Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of TreatmentGlobeNewsWire • 08/24/22
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/22
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH FibrosisGlobeNewsWire • 06/27/22
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap BiopharmaBenzinga • 06/16/22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 MillionGlobeNewsWire • 06/16/22
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASHGlobeNewsWire • 06/13/22
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/25/22
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH PatientsGlobeNewsWire • 02/08/22
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/14/22
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual ConferenceGlobeNewsWire • 11/26/21
Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a BetZacks Investment Research • 11/17/21
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of TreatmentGlobeNewsWire • 11/12/21
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/21
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASHGlobeNewsWire • 10/19/21
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor ConferenceGlobeNewsWire • 10/05/21
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/21
Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of TreatmentBenzinga • 07/08/21
Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of TreatmentGlobeNewsWire • 07/08/21
Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-GlobeNewsWire • 06/25/21